Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VRCD Regimen in Low-grade Non-Hodgkin's Lymphoma
NCT00413959Phase 2Terminated
- Sponsor
- Oncology Specialists
- Start
- Aug 2006
- Primary completion
- Jan 2011
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bortezomib in non-Hodgkin lymphoma (NHL), sponsored by Oncology Specialists. Primary endpoint: Overall Response Rate at 4 years. Started Aug 2006; status: terminated.
02
Drugs
bortezomib
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT00413959.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00413959.